Syndax Leverages Commercial Success to Fund High-Risk Pipeline with No Supporting Data

Syndax Reports Strong Q2 2026 Revenue and Pipeline Progress

Syndax Pharmaceuticals reported strong financial results for the second quarter ended June 30, 2026, with total revenue reaching $72.8 million, a 92% year-over-year increase. This growth was driven by significant net revenue from its commercial products, Revuforj (revumenib) at $54.7 million (+91% YoY) and Niktimvo (axatilimab-csfr) at $60.3 million (+67% YoY). The company also expanded its pipeline by introducing SNDX-4321, a novel EGFR inhibitor for NSCLC, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis. Key clinical milestones are anticipated in Q4 2026, including topline data for axatilimab in IPF and frontline cGVHD.

• Syndax achieved robust commercial performance in Q2 2026, with Revuforj net revenue increasing 91% year-over-year to $54.7 million, driven by approximately 1,500 prescriptions and an increasing average treatment duration. Niktimvo net revenue also grew 67% year-over-year to $60.3 million, contributing $18.1 million in collaboration revenue for Syndax.
• The company strategically expanded its pipeline by announcing two new assets: SNDX-4321, a mutant-selective, allosteric EGFR inhibitor for NSCLC with an Investigational New Drug (IND) application planned by the end of 2026, and SNDX-62122, a next-generation menin inhibitor for myelofibrosis, with an IND planned for 2027.
• Syndax anticipates several near-term clinical catalysts, including topline data in Q4 2026 from Phase 2 trials of axatilimab in idiopathic pulmonary fibrosis (MAXPIRe trial) and in frontline chronic graft-versus-host disease. Additionally, new and updated revumenib data, encompassing real-world evidence and frontline data from the BEAT AML and SAVE trials, are expected in the second half of 2026.

Expanding Revuforj's Reach Across the Acute Leukemia Continuum

Beyond its approved indications in relapsed/refractory (R/R) acute leukemia, Revumenib is being actively investigated across the treatment continuum. Clinical development is exploring its potential in the frontline setting for newly diagnosed patients and as a maintenance therapy following allogeneic stem cell transplantation. A key strategic focus is the evaluation of Revumenib in various combination regimens to enhance efficacy and address potential resistance mechanisms.

Addressing Critical Unmet Needs in Relapsed/Refractory AML

Despite recent therapeutic advances, relapsed/refractory acute myeloid leukemia (R/R AML) continues to be characterized by an extremely poor prognosis and limited survival. The failure of many patients to respond to or maintain remission with novel agents underscores the critical need to address therapy-resistant disease and define strategies for specific high-risk populations.

• Overcoming Widespread Treatment Failure: A primary unmet need is the lack of effective options for patients who fail existing therapies, resulting in dismal survival. This includes a significant number of patients who do not achieve remission with venetoclax-based regimens (74.3% in one cohort) and those with specific mutations who exhibit no response to the best available targeted agents. With no clearly established standard of care for primary refractory or relapsed disease, developing therapies that can induce durable remission remains a major challenge.

• Addressing Limitations of Advanced Therapies: The clinical application of CAR T-cell therapy in R/R AML is severely restricted by off-target effects causing severe bone marrow suppression and the lack of a truly leukemia-specific antigen. Consequently, patients who fail investigational CAR-T therapies are left with no effective treatment options, highlighting the need for better target selection and strategies to overcome the immunosuppressive tumor microenvironment.

• Targeting Therapy-Resistant Leukemic Stem Cells (LSCs): Relapse in AML is largely attributed to the persistence of therapy-resistant LSCs, which possess self-renewal and repopulating capabilities. Developing novel therapeutic approaches that can effectively eradicate this LSC population is considered one of the most promising avenues for achieving long-term disease management and preventing recurrence.

• Focusing on High-Risk Clinical Populations: Drug development is increasingly targeting patient cohorts with particularly poor outcomes. This includes older adults, patients ineligible for intensive chemotherapy or allogeneic stem cell transplantation, and heavily pre-treated individuals who have relapsed after multiple lines of therapy or failed to achieve hematopoietic recovery post-CAR-T.

• Tailoring Therapies for Genomically-Defined Subgroups: A key area of investigation involves targeting specific molecularly-defined patient populations. These include patients harboring mutations in genes such as IDH1/2, NPM1, DNMT3A, and TET2; those with KMT2A rearrangements; and individuals with spliceosomal mutations (e.g., SF3B1, SRSF2, U2AF1), which occur frequently in AML and MDS.